poisar

Stock

United Therapeutics Corporation UTHR

$517.71-1.54%

Overview

UTHR market data

Price History

UTHR price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
17.17
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$27.86
Diluted earnings per share over the trailing twelve months.
Beta
0.57
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$272.12 – $609.35
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $22.1K · P/B 2.96 · P/S 6.97.

Company News

10 captured
United Therapeutics Announces Publication of ADVANCE OUTCOMES Study in The Lancet; Ralinepag Remains Investigational for PAHBenzinga · Jul 29, 2026, 10:37 AM
United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?The Motley Fool · Jul 28, 2026, 10:15 PM
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687Benzinga · Jul 23, 2026, 6:47 PM
8-K filing — UNITED THERAPEUTICS Corp (UTHR)SEC EDGAR · Jul 23, 2026, 11:00 AM
B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613Benzinga · Jul 10, 2026, 6:10 PM
BETA Completes First FAA eIPP Electric Aircraft Flights, Transporting Manufactured Organs For United TherapeuticsBenzinga · Jul 10, 2026, 4:40 PM
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $704Benzinga · Jul 7, 2026, 4:30 PM
United Therapeutics Expands Immune Therapy Pipeline With ThymmuneBenzinga · Jul 2, 2026, 1:10 PM
FDA Approval Positions United Therapeutics To Broaden Access To Donor LungsBenzinga · Jun 29, 2026, 4:55 PM
iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF ReturnsThe Motley Fool · Jun 10, 2026, 7:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock